Quels espoirs pour l'hépatite delta ?

Article Article scientifique Article Quels espoirs pour l'hépatite delta ? fre 2016 author Guglielmi Stefano 554170 author Frossard Jean-Louis 35038 author Negro Francesco 96509 1415-1418 28675280 1660-9379 Hepatitis D or delta is a chronic liver disease globally reaching 15‑20M people. Its agent, hepatitis D virus (HDV) requires the presence of hepatitis B virus (HBV) to complete its life cycle. It represents one of the most severe forms of viral hepatitis. Current therapy with pegylated interferon alpha leads to viral eradication only in 25 % of cases. New treatments targeting the virus life cycle are sought. For example Myrcludex-B, which inhibits the entry into hepatocytes, lonafarnib which prevents the assemblage of the viral particle and the molecule REP 2139 which, among other unclear mechanisms, impedes the exit of the virus. This allows considering a better management of a condition for which there is currently no satisfactory treatment. Dewey 616 Dewey 616.07 137 Département de pathologie et immunologie 21F 56 Département de médecine 221 false 297 Etudes et traitement de l'hépatite C et B 554 335 Pancréatite aiguë 601 Revue médicale suisse 12 528 aa3578ee-e493-4385-b9eb-956373b51bf6 Article (Published version) Restricted Quel.pdf 958569 application/pdf restrictedAccess Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie Faculté de médecine / Section de médecine clinique / Département de médecine

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Quels espoirs pour l'hépatite delta ?	Revue médicale suisse			2016	442	1

Archive ouverte UNIGE

Guglielmi, Stefano